Compare Inovio Pharmaceuticals Inc (INO) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs JetBlue Airways Corporation — how do they compare? Inovio Pharmaceuticals Inc trades at $0.76 (market cap $78.55M), while JetBlue Airways Corporation trades at $5.86 (market cap $2.19B). The key difference: JetBlue Airways Corporation is far larger — about 27.9× Inovio Pharmaceuticals Inc's market cap, and JetBlue Airways Corporation is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | JBLU | |
|---|---|---|
Market Cap | $78.55M | $2.19B |
Sector | Health | Industrials |
52-Week High | $2.87 | $6.46 |
52-Week Low | $0.66 | $4.03 |
Enterprise Value | $49.56M | $9.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
JetBlue (JBLU) trades at $5.87, up 4.08% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings beat with a loss of $0.66 per share versus expectations of $0.69, though it has missed estimates in two of the last three quarters. Recent news includes Citigroup's downgrade to Sell on August 11, 2026, citing geopolitical risks, while the company introduced new fare structures and lounge accolades.
Outlook remains challenging with persistent net losses and negative margins, but cost management and strategic initiatives like the 2028 profit target offer potential upside. Key risks include high fuel costs, debt levels, and competitive pressure. Analyst consensus is cautious with a $5.18 price target and 62% Hold ratings, suggesting limited near-term growth amid operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
